CD8+ T cells protect against tumors and intracellular pathogens. The inflammatory cytokines IL-2, IL-15, and IL-7 are necessary for their expansion. However, elevated serum levels of these cytokines are often associated with cancer, poorer prognosis of cancer patients, and exhaustion of antigen-expanded CD8+ T cells. The impact of acute conditioning of antigen-expanded CD8+ T cells with these cytokines is unknown. Here, we generated antigen-expanded CD8+ T cells using dendritic cells and PC-3 cells. The cells were acutely (18-24 h) conditioned with IL-2 and either the GSK3β inhibitor TWS119, the mTORC1 inhibitor rapamycin, or the mTORC1/2 inhibitor Torin1, then their immediate and post-re-expansion (distal) cytokine responses after antigen rechallenge were evaluated. We found that acute IL-2 conditioning upregulated the immediate antigen-induced cytokine response of the tested cells. Following their re-expansion, however, the cells showed a decreased cytokine response. These IL-2 conditioning-mediated impacts were counteracted with TWS119 or rapamycin but not with Torin1. Our data revealed that the acute conditioning of antigen-expanded CD8+ T cells with IL-2 modulates the GSK3β-mTORC signaling axis. This modulation differentially affected the immediate and distal cytokine responses of the cells. The acute targeting of this signaling axis could, therefore, represent a novel strategy for the modulation of antigen-expanded CD8+ T cells.

Department of Immunology 2nd Faculty of Medicine Charles University and University Hospital Motol 15006 Prague Czech Republic

Zobrazit více v PubMed

Jain A., Pasare C. Innate Control of Adaptive Immunity: Beyond the Three-Signal Paradigm. J. Immunol. 2017;198:3791–3800. doi: 10.4049/jimmunol.1602000. PubMed DOI PMC

Liu Q., Sun Z., Chen L. Memory T cells: Strategies for optimizing tumor immunotherapy. Protein Cell. 2020 doi: 10.1007/s13238-020-00707-9. PubMed DOI PMC

Dwyer C.J., Knochelmann H.M., Smith A.S., Wyatt M.M., Rangel Rivera G.O., Arhontoulis D.C., Bartee E., Li Z., Rubinstein M.P., Paulos C.M. Fueling Cancer Immunotherapy With Common Gamma Chain Cytokines. Front. Immunol. 2019;10:263. doi: 10.3389/fimmu.2019.00263. PubMed DOI PMC

Mahallawi W.H., Khabour O.F., Zhang Q., Makhdoum H.M., Suliman B.A. MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile. Cytokine. 2018;104:8–13. doi: 10.1016/j.cyto.2018.01.025. PubMed DOI PMC

Wong C.K., Lam C.W., Wu A.K., Ip W.K., Lee N.L., Chan I.H., Lit L.C., Hui D.S., Chan M.H., Chung S.S., et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin. Exp. Immunol. 2004;136:95–103. doi: 10.1111/j.1365-2249.2004.02415.x. PubMed DOI PMC

Younes S.A., Freeman M.L., Mudd J.C., Shive C.L., Reynaldi A., Panigrahi S., Estes J.D., Deleage C., Lucero C., Anderson J., et al. IL-15 promotes activation and expansion of CD8+ T cells in HIV-1 infection. J. Clin. Investig. 2016;126:2745–2756. doi: 10.1172/JCI85996. PubMed DOI PMC

Kucera R., Topolcan O., Treskova I., Kinkorova J., Windrichova J., Fuchsova R., Svobodova S., Treska V., Babuska V., Novak J., et al. Evaluation of IL-2, IL-6, IL-8 and IL-10 in Malignant Melanoma Diagnostics. Anticancer. Res. 2015;35:3537–3541. PubMed

Rosenberg S.A. IL-2: The first effective immunotherapy for human cancer. J. Immunol. 2014;192:5451–5458. doi: 10.4049/jimmunol.1490019. PubMed DOI PMC

Kochenderfer J.N., Somerville R.P.T., Lu T., Shi V., Bot A., Rossi J., Xue A., Goff S.L., Yang J.C., Sherry R.M., et al. Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2017;35:1803–1813. doi: 10.1200/JCO.2016.71.3024. PubMed DOI PMC

Rosenberg S.A., Restifo N.P. Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015;348:62–68. doi: 10.1126/science.aaa4967. PubMed DOI PMC

McLane L.M., Abdel-Hakeem M.S., Wherry E.J. CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer. Annu. Rev. Immunol. 2019;37:457–495. doi: 10.1146/annurev-immunol-041015-055318. PubMed DOI

Granier C., Dariane C., Combe P., Verkarre V., Urien S., Badoual C., Roussel H., Mandavit M., Ravel P., Sibony M., et al. Tim-3 Expression on Tumor-Infiltrating PD-1(+)CD8(+) T Cells Correlates with Poor Clinical Outcome in Renal Cell Carcinoma. Cancer Res. 2017;77:1075–1082. doi: 10.1158/0008-5472.CAN-16-0274. PubMed DOI

McKinney E.F., Lee J.C., Jayne D.R., Lyons P.A., Smith K.G. T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection. Nature. 2015;523:612–616. doi: 10.1038/nature14468. PubMed DOI PMC

Shimabukuro-Vornhagen A., Godel P., Subklewe M., Stemmler H.J., Schlosser H.A., Schlaak M., Kochanek M., Boll B., von Bergwelt-Baildon M.S. Cytokine release syndrome. J. Immunother. Cancer. 2018;6:56. doi: 10.1186/s40425-018-0343-9. PubMed DOI PMC

Gattinoni L., Klebanoff C.A., Restifo N.P. Pharmacologic induction of CD8+ T cell memory: Better living through chemistry. Sci. Transl. Med. 2009;1:11ps12. doi: 10.1126/scitranslmed.3000302. PubMed DOI PMC

Pearce E.L., Walsh M.C., Cejas P.J., Harms G.M., Shen H., Wang L.S., Jones R.G., Choi Y. Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature. 2009;460:103–107. doi: 10.1038/nature08097. PubMed DOI PMC

Marro B.S., Zak J., Zavareh R.B., Teijaro J.R., Lairson L.L., Oldstone M.B.A. Discovery of Small Molecules for the Reversal of T Cell Exhaustion. Cell Rep. 2019;29:3293–3302 e3293. doi: 10.1016/j.celrep.2019.10.119. PubMed DOI PMC

Kishton R.J., Sukumar M., Restifo N.P. Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy. Cell Metab. 2017;26:94–109. doi: 10.1016/j.cmet.2017.06.016. PubMed DOI PMC

Zhang L., Romero P. Metabolic Control of CD8(+) T Cell Fate Decisions and Antitumor Immunity. Trends Mol. Med. 2018;24:30–48. doi: 10.1016/j.molmed.2017.11.005. PubMed DOI

Benczik M., Gaffen S.L. The interleukin (IL)-2 family cytokines: Survival and proliferation signaling pathways in T lymphocytes. Immunol. Investig. 2004;33:109–142. doi: 10.1081/IMM-120030732. PubMed DOI

Taylor H.E., Calantone N.A., D’Aquila R.T. mTOR signaling mediates effects of common gamma-chain cytokines on T cell proliferation and exhaustion: Implications for HIV-1 persistence and cure research. Aids. 2018;32:2847–2851. doi: 10.1097/QAD.0000000000001997. PubMed DOI PMC

Ross S.H., Cantrell D.A. Signaling and Function of Interleukin-2 in T Lymphocytes. Annu. Rev. Immunol. 2018;36:411–433. doi: 10.1146/annurev-immunol-042617-053352. PubMed DOI PMC

Avery L., Filderman J., Szymczak-Workman A.L., Kane L.P. Tim-3 co-stimulation promotes short-lived effector T cells, restricts memory precursors, and is dispensable for T cell exhaustion. Proc. Natl. Acad. Sci. USA. 2018;115:2455–2460. doi: 10.1073/pnas.1712107115. PubMed DOI PMC

Shan B., Man H., Liu J., Wang L., Zhu T., Ma M., Xv Z., Chen X., Yang X., Li P. TIM-3 promotes the metastasis of esophageal squamous cell carcinoma by targeting epithelial-mesenchymal transition via the Akt/GSK-3beta/Snail signaling pathway. Oncol. Rep. 2016;36:1551–1561. doi: 10.3892/or.2016.4938. PubMed DOI

Pallet N., Legendre C. Adverse events associated with mTOR inhibitors. Expert Opin. Drug Saf. 2013;12:177–186. doi: 10.1517/14740338.2013.752814. PubMed DOI

Nabben M., Neumann D. GSK-3 Inhibitors: Anti-Diabetic Treatment Associated with Cardiac Risk? Editorial to: “The Impact of Chronic Glycogen Synthase Kinase-3 Inhibition on Remodeling of Normal and Pre-Diabetic Rat Hearts.” by Barbara Huisamen et al. Cardiovasc. Drugs Ther. 2016;30:233–235. doi: 10.1007/s10557-016-6669-y. PubMed DOI

Smrž D., Bandara G., Beaven M.A., Metcalfe D.D., Gilfillan A.M. Prevention of F-actin assembly switches the response to SCF from chemotaxis to degranulation in human mast cells. Eur. J. Immunol. 2013;43:1873–1882. doi: 10.1002/eji.201243214. PubMed DOI PMC

Ito T., Smrž D., Jung M.Y., Bandara G., Desai A., Smržová S., Kuehn H.S., Beaven M.A., Metcalfe D.D., Gilfillan A.M. Stem Cell Factor Programs the Mast Cell Activation Phenotype. J. Immunol. 2012;188:5428–5437. doi: 10.4049/jimmunol.1103366. PubMed DOI PMC

Jung M.Y., Smrž D., Desai A., Bandara G., Ito T., Iwaki S., Kang J.H., Andrade M.V., Hilderbrand S.C., Brown J.M., et al. IL-33 Induces a Hyporesponsive Phenotype in Human and Mouse Mast Cells. J. Immunol. 2013;190:531–538. doi: 10.4049/jimmunol.1201576. PubMed DOI PMC

Mujib S., Jones R.B., Lo C., Aidarus N., Clayton K., Sakhdari A., Benko E., Kovacs C., Ostrowski M.A. Antigen-independent induction of Tim-3 expression on human T cells by the common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 is associated with proliferation and is dependent on the phosphoinositide 3-kinase pathway. J. Immunol. 2012;188:3745–3756. doi: 10.4049/jimmunol.1102609. PubMed DOI

Zhu C., Anderson A.C., Schubart A., Xiong H., Imitola J., Khoury S.J., Zheng X.X., Strom T.B., Kuchroo V.K. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat. Immunol. 2005;6:1245–1252. doi: 10.1038/ni1271. PubMed DOI

Anderson A.C., Joller N., Kuchroo V.K. Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation. Immunity. 2016;44:989–1004. doi: 10.1016/j.immuni.2016.05.001. PubMed DOI PMC

Fan M.Y., Turka L.A. Immunometabolism and PI(3)K Signaling As a Link between IL-2, Foxp3 Expression, and Suppressor Function in Regulatory T Cells. Front. Immunol. 2018;9:69. doi: 10.3389/fimmu.2018.00069. PubMed DOI PMC

Rao R.R., Li Q., Odunsi K., Shrikant P.A. The mTOR kinase determines effector versus memory CD8+ T cell fate by regulating the expression of transcription factors T-bet and Eomesodermin. Immunity. 2010;32:67–78. doi: 10.1016/j.immuni.2009.10.010. PubMed DOI PMC

Macintyre A.N., Finlay D., Preston G., Sinclair L.V., Waugh C.M., Tamas P., Feijoo C., Okkenhaug K., Cantrell D.A. Protein kinase B controls transcriptional programs that direct cytotoxic T cell fate but is dispensable for T cell metabolism. Immunity. 2011;34:224–236. doi: 10.1016/j.immuni.2011.01.012. PubMed DOI PMC

Azoulay-Alfaguter I., Elya R., Avrahami L., Katz A., Eldar-Finkelman H. Combined regulation of mTORC1 and lysosomal acidification by GSK-3 suppresses autophagy and contributes to cancer cell growth. Oncogene. 2015;34:4613–4623. doi: 10.1038/onc.2014.390. PubMed DOI

Taylor A., Harker J.A., Chanthong K., Stevenson P.G., Zuniga E.I., Rudd C.E. Glycogen Synthase Kinase 3 Inactivation Drives T-bet-Mediated Downregulation of Co-receptor PD-1 to Enhance CD8(+) Cytolytic T Cell Responses. Immunity. 2016;44:274–286. doi: 10.1016/j.immuni.2016.01.018. PubMed DOI PMC

Ding S., Wu T.Y., Brinker A., Peters E.C., Hur W., Gray N.S., Schultz P.G. Synthetic small molecules that control stem cell fate. Proc. Natl. Acad. Sci. USA. 2003;100:7632–7637. doi: 10.1073/pnas.0732087100. PubMed DOI PMC

Stakheev D., Taborska P., Strizova Z., Podrazil M., Bartunkova J., Smrz D. The WNT/beta-catenin signaling inhibitor XAV939 enhances the elimination of LNCaP and PC-3 prostate cancer cells by prostate cancer patient lymphocytes in vitro. Sci. Rep. 2019;9:4761. doi: 10.1038/s41598-019-41182-5. PubMed DOI PMC

Jhanwar-Uniyal M., Wainwright J.V., Mohan A.L., Tobias M.E., Murali R., Gandhi C.D., Schmidt M.H. Diverse signaling mechanisms of mTOR complexes: mTORC1 and mTORC2 in forming a formidable relationship. Adv. Biol. Regul. 2019;72:51–62. doi: 10.1016/j.jbior.2019.03.003. PubMed DOI

Gibbons J.J., Abraham R.T., Yu K. Mammalian target of rapamycin: Discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth. Semin. Oncol. 2009;36(Suppl. S3):S3–S17. doi: 10.1053/j.seminoncol.2009.10.011. PubMed DOI

Thoreen C.C., Kang S.A., Chang J.W., Liu Q., Zhang J., Gao Y., Reichling L.J., Sim T., Sabatini D.M., Gray N.S. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J. Biol. Chem. 2009;284:8023–8032. doi: 10.1074/jbc.M900301200. PubMed DOI PMC

Oubrahim H., Wong A., Wilson B.A., Chock P.B. Mammalian target of rapamycin complex 1 (mTORC1) plays a role in Pasteurella multocida toxin (PMT)-induced protein synthesis and proliferation in Swiss 3T3 cells. J. Biol. Chem. 2013;288:2805–2815. doi: 10.1074/jbc.M112.427351. PubMed DOI PMC

Meyuhas O. Ribosomal Protein S6 Phosphorylation: Four Decades of Research. Int. Rev. Cell Mol. Biol. 2015;320:41–73. doi: 10.1016/bs.ircmb.2015.07.006. PubMed DOI

Abdel-Hakeem M.S., Boisvert M., Bruneau J., Soudeyns H., Shoukry N.H. Selective expansion of high functional avidity memory CD8 T cell clonotypes during hepatitis C virus reinfection and clearance. PLoS Pathog. 2017;13:e1006191. doi: 10.1371/journal.ppat.1006191. PubMed DOI PMC

Pollizzi K.N., Patel C.H., Sun I.H., Oh M.H., Waickman A.T., Wen J., Delgoffe G.M., Powell J.D. mTORC1 and mTORC2 selectively regulate CD8(+) T cell differentiation. J. Clin. Investig. 2015;125:2090–2108. doi: 10.1172/JCI77746. PubMed DOI PMC

Hope J.L., Stairiker C.J., Bae E.A., Otero D.C., Bradley L.M. Striking a Balance-Cellular and Molecular Drivers of Memory T Cell Development and Responses to Chronic Stimulation. Front. Immunol. 2019;10:1595. doi: 10.3389/fimmu.2019.01595. PubMed DOI PMC

Bucks C.M., Norton J.A., Boesteanu A.C., Mueller Y.M., Katsikis P.D. Chronic antigen stimulation alone is sufficient to drive CD8+ T cell exhaustion. J. Immunol. 2009;182:6697–6708. doi: 10.4049/jimmunol.0800997. PubMed DOI PMC

Tang R., Rangachari M., Kuchroo V.K. Tim-3: A co-receptor with diverse roles in T cell exhaustion and tolerance. Semin. Immunol. 2019;42:101302. doi: 10.1016/j.smim.2019.101302. PubMed DOI

Mengus C., Le Magnen C., Trella E., Yousef K., Bubendorf L., Provenzano M., Bachmann A., Heberer M., Spagnoli G.C., Wyler S. Elevated levels of circulating IL-7 and IL-15 in patients with early stage prostate cancer. J. Transl. Med. 2011;9:162. doi: 10.1186/1479-5876-9-162. PubMed DOI PMC

Pandiyan P., Zheng L., Ishihara S., Reed J., Lenardo M.J. CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. Nat. Immunol. 2007;8:1353–1362. doi: 10.1038/ni1536. PubMed DOI

Zago C.A., Bortoluci K.R., Sardinha L.R., Pretel F.D., Castillo-Mendez S.I., Freitas do Rosario A.P., Hiyane M.I., Muxel S.M., Rodriguez-Malaga S.M., Abrahamsohn I.A., et al. Anti-IL-2 treatment impairs the expansion of T(reg) cell population during acute malaria and enhances the Th1 cell response at the chronic disease. PLoS ONE. 2012;7:e29894. doi: 10.1371/journal.pone.0029894. PubMed DOI PMC

Benson A., Murray S., Divakar P., Burnaevskiy N., Pifer R., Forman J., Yarovinsky F. Microbial infection-induced expansion of effector T cells overcomes the suppressive effects of regulatory T cells via an IL-2 deprivation mechanism. J. Immunol. 2012;188:800–810. doi: 10.4049/jimmunol.1100769. PubMed DOI PMC

Sananez I., Raiden S., Erra-Diaz F., De Lillo L., Holgado M.P., Geffner J., Arruvito L. Dampening of IL-2 Function in Infants With Severe Respiratory Syncytial Virus Disease. J. Infect. Dis. 2018;218:75–83. doi: 10.1093/infdis/jiy180. PubMed DOI

Cerezo A., Martinez A.C., Gonzalez A., Gomez J., Rebollo A. IL-2 deprivation triggers apoptosis which is mediated by c-Jun N-terminal kinase 1 activation and prevented by Bcl-2. Cell Death Differ. 1999;6:87–94. doi: 10.1038/sj.cdd.4400458. PubMed DOI

Forsdyke D.R. Metabolic optimization of adoptive T cell transfer cancer immunotherapy: A historical overview. Scand. J. Immunol. 2020;92:e12929. doi: 10.1111/sji.12929. PubMed DOI

Richardson N.H., Luttrell J.B., Bryant J.S., Chamberlain D., Khawaja S., Neeli I., Radic M. Tuning the performance of CAR T cell immunotherapies. BMC Biotechnol. 2019;19:84. doi: 10.1186/s12896-019-0576-9. PubMed DOI PMC

Yamamoto T.N., Lee P.H., Vodnala S.K., Gurusamy D., Kishton R.J., Yu Z., Eidizadeh A., Eil R., Fioravanti J., Gattinoni L., et al. T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy. J. Clin. Investig. 2019;129:1551–1565. doi: 10.1172/JCI121491. PubMed DOI PMC

Lozano T., Chocarro S., Martin C., Lasarte-Cia A., Del Valle C., Gorraiz M., Sarrion P., Ruiz de Galarreta M., Lujambio A., Hervas-Stubbs S., et al. Genetic Modification of CD8(+) T Cells to Express EGFR: Potential Application for Adoptive T Cell Therapies. Front. Immunol. 2019;10:2990. doi: 10.3389/fimmu.2019.02990. PubMed DOI PMC

Zhang J.Y., Zhao Y.L., Lv Y.P., Cheng P., Chen W., Duan M., Teng Y.S., Wang T.T., Peng L.S., Mao F.Y., et al. Modulation of CD8(+) memory stem T cell activity and glycogen synthase kinase 3beta inhibition enhances anti-tumoral immunity in gastric cancer. Oncoimmunology. 2018;7:e1412900. doi: 10.1080/2162402X.2017.1412900. PubMed DOI PMC

Langdon S., Hughes A., Taylor M.A., Kuczynski E.A., Mele D.A., Delpuech O., Jarvis L., Staniszewska A., Cosulich S., Carnevalli L.S., et al. Combination of dual mTORC1/2 inhibition and immune-checkpoint blockade potentiates anti-tumour immunity. Oncoimmunology. 2018;7:e1458810. doi: 10.1080/2162402X.2018.1458810. PubMed DOI PMC

Rostamzadeh D., Yousefi M., Haghshenas M.R., Ahmadi M., Dolati S., Babaloo Z. mTOR Signaling pathway as a master regulator of memory CD8(+) T-cells, Th17, and NK cells development and their functional properties. J. Cell Physiol. 2019;234:12353–12368. doi: 10.1002/jcp.28042. PubMed DOI

Zheng Y., Jiang Y. mTOR Inhibitors at a Glance. Mol. Cell. Pharmacol. 2015;7:15–20. PubMed PMC

Zou Z., Tao T., Li H., Zhu X. mTOR signaling pathway and mTOR inhibitors in cancer: Progress and challenges. Cell Biosci. 2020;10:31. doi: 10.1186/s13578-020-00396-1. PubMed DOI PMC

McCubrey J.A., Steelman L.S., Bertrand F.E., Davis N.M., Sokolosky M., Abrams S.L., Montalto G., D’Assoro A.B., Libra M., Nicoletti F., et al. GSK-3 as potential target for therapeutic intervention in cancer. Oncotarget. 2014;5:2881–2911. doi: 10.18632/oncotarget.2037. PubMed DOI PMC

Thoreen C.C., Sabatini D.M. Rapamycin inhibits mTORC1, but not completely. Autophagy. 2009;5:725–726. doi: 10.4161/auto.5.5.8504. PubMed DOI

Chen C.H., Shaikenov T., Peterson T.R., Aimbetov R., Bissenbaev A.K., Lee S.W., Wu J., Lin H.K., Sarbassov dos D. ER stress inhibits mTORC2 and Akt signaling through GSK-3beta-mediated phosphorylation of rictor. Sci. Signal. 2011;4:ra10. doi: 10.1126/scisignal.2001731. PubMed DOI

Kazyken D., Magnuson B., Bodur C., Acosta-Jaquez H.A., Zhang D., Tong X., Barnes T.M., Steinl G.K., Patterson N.E., Altheim C.H., et al. AMPK directly activates mTORC2 to promote cell survival during acute energetic stress. Sci. Signal. 2019:12. doi: 10.1126/scisignal.aav3249. PubMed DOI PMC

Yin Y., Mitson-Salazar A., Wansley D.L., Singh S.P., Prussin C. Rapamycin preferentially inhibits human IL-5(+) TH2-cell proliferation via an mTORC1/S6 kinase-1-dependent pathway. J. Allergy Clin. Immunol. 2017;139:1701–1704 e1710. doi: 10.1016/j.jaci.2016.10.029. PubMed DOI

Taffs R.E., Redegeld F.A., Sitkovsky M.V. Modulation of cytolytic T lymphocyte functions by an inhibitor of serine/threonine phosphatase, okadaic acid. Enhancement of cytolytic T lymphocyte-mediated cytotoxicity. J. Immunol. 1991;147:722–728. PubMed

Taborska P., Bartunkova J., Smrz D. Simultaneous in vitro generation of human CD34(+)-derived dendritic cells and mast cells from non-mobilized peripheral blood mononuclear cells. J. Immunol. Methods. 2018;458:63–73. doi: 10.1016/j.jim.2018.04.005. PubMed DOI

Kaighn M.E., Narayan K.S., Ohnuki Y., Lechner J.F., Jones L.W. Establishment and characterization of a human prostatic carcinoma cell line (PC-3) Investig. Urol. 1979;17:16–23. PubMed

Smrž D., Dráberová L., Dráber P. Non-apoptotic phosphatidylserine externalization induced by engagement of glycosylphosphatidylinositol-anchored proteins. J. Biol. Chem. 2007;282:10487–10497. doi: 10.1074/jbc.M611090200. PubMed DOI

Impaired Proliferation of CD8+ T Cells Stimulated with Monocyte-Derived Dendritic Cells Previously Matured with Thapsigargin-Stimulated LAD2 Human Mast Cells

Novel PD-L1- and collagen-expressing patient-derived cell line of undifferentiated pleomorphic sarcoma (JBT19) as a model for cancer immunotherapy

LL-37 as a Powerful Molecular Tool for Boosting the Performance of Ex Vivo-Produced Human Dendritic Cells for Cancer Immunotherapy

SARS-CoV-2 spike glycoprotein-reactive T cells can be readily expanded from COVID-19 vaccinated donors

Thapsigargin-Stimulated LAD2 Human Mast Cell Line Is a Potent Cellular Adjuvant for the Maturation of Monocyte-Derived Dendritic Cells for Adoptive Cellular Immunotherapy